{"name":"ProMIS Neurosciences","slug":"promis","ticker":"PMN","exchange":"TSX","domain":"promisneurosciences.com","description":"ProMIS Neurosciences is a biotechnology company focused on the development of precision antibodies for the treatment of neurodegenerative diseases. The company's lead programs target Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. ProMIS Neurosciences has a pipeline of therapeutic candidates in various stages of development, with a focus on precision medicine and targeted therapies. The company is positioned to capitalize on the growing demand for innovative treatments in the neuroscience space.","hq":"Toronto, ON, Canada","founded":0,"employees":"","ceo":"Gail Bhargava","sector":"Neuroscience Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":33379321,"netIncome":-39719147,"cash":6116556,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PMN-310 patent cliff ($0.0B at risk)","drug":"PMN-310","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"PMN-301 patent cliff ($0.0B at risk)","drug":"PMN-301","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"ProMIS Neurosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"ProMIS Neurosciences reported its fourth quarter and full year 2023 financial results, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"ProMIS Neurosciences Enters into Research Collaboration with Biogen","summary":"ProMIS Neurosciences entered into a research collaboration with Biogen to develop precision antibodies for the treatment of neurodegenerative diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1hZjBnNG1NUGdlZkFwVll3T0ZiMmM4eE0xWTU1anVwMUpNMWhiUGp2TlhCQ3piQThocDhtQkVRa0JPV2xWUTNIY0ZTUnB0Snhwcmh4c0dqaTZLZ3ozWDB1eWtfZlZRYjV2TG05eg?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan","headline":"If You Invested $1,000 in Promis Neuroscie (PMN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-24","type":"pipeline","source":"simplywall.st","summary":"ProMIS Neurosciences (NASDAQ:PMN) Will Have To Spend Its Cash Wisely - simplywall.st","headline":"ProMIS Neurosciences (NASDAQ:PMN) Will Have To Spend Its Cash Wisely","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPMWFfdUdkZnA3ZXZoLWplUjFseUhrVDVJUTA0aGhXa2pRbXBzSUI2bHZTRGRDUE9ydTJXVzg5d19PbjllWG1rT1BzNjlydEZPWVFfWHZ3Ykl5bGlmYTRGZFJ3eE9yVmQ3WUtrY0xac21iOVlYSzRISVlyUXg2VXdLcTFoR2FfSVNNbDN5aGU0SWl1YldGYlhIU1dNMmV4OE5ka3dQazNjd1JlQW0tT0dKTUdKVkplN3FZU3gtSlk1NlN4MWFQUkxxY3I5bElzU2MxS3ppeGpORW5GQnl5UmVibjJpZjJPSEo2VFh2RVl5TXpxYlpaNGM0SV9GdHFmd3AzUEhCQTZibkhvR0M2U2ZWRW5ZNmtXc3E4aTBjSVlSS2lfUzRIT0lFbzVUckZjWDNsZ2JPVjBCRlRfTzhaU1FBcFVTUzU?oc=5","date":"2025-10-22","type":"pipeline","source":"GlobeNewswire","summary":"ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group - GlobeNewswire","headline":"ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-15","type":"pipeline","source":"simplywall.st","summary":"ProMIS Neurosciences Insiders Still US$234k Away From Original Investment Value - simplywall.st","headline":"ProMIS Neurosciences Insiders Still US$234k Away From Original Investment Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9INThKajlYM0NOVE01Y0hTU2k3cUh3WVc2c1diMVhkNlpDclBrYU9Ud0JjZGJDQ2F2TkhjdFRwMS1pcW5CNEpWbWtJcVBLNlBJ?oc=5","date":"2024-04-04","type":"pipeline","source":"Yahoo! Finance Canada","summary":"ProMIS Neurosciences, Inc. (PMN) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"ProMIS Neurosciences, Inc. (PMN) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9UUTdqZUx1S250NUlNYlJqUnBoOGlqWmdzY01neXlBcjVjOXVENHNjYmFhT0VUUGJ1YXRoVVFMX3NwalpWOU83dHdfNmxIZ0dz?oc=5","date":"2024-03-06","type":"pipeline","source":"Yahoo Finance Singapore","summary":"ProMIS Neurosciences, Inc. (PMN) stock price, news, quote and history - Yahoo Finance Singapore","headline":"ProMIS Neurosciences, Inc. (PMN) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1Wb3d4bk9hZ0llVFJERC1QaXZydjJDdEpqd1g5VXk5SXp1RmUzMUxqMDRBZ3Nla2p4aVd3OTJXTy1FWHl0WTY0Y0R5Nlc?oc=5","date":"2022-09-14","type":"pipeline","source":"Stock Titan","summary":"Latest PMN News - ProMIS Neurosciences Announces Full Year 202... - Stock Titan","headline":"Latest PMN News - ProMIS Neurosciences Announces Full Year 202...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-09-13","type":"pipeline","source":"Greatreporter","summary":"ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer - Greatreporter","headline":"ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer","sentiment":"neutral"}],"patents":[{"drugName":"PMN-310","drugSlug":"pmn-310","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PMN-301","drugSlug":"pmn-301","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Eli Lilly and Company","Johnson & Johnson"],"therapeuticFocus":["Alzheimer's disease","Amyotrophic lateral sclerosis (ALS)"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":33379321,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-39719147,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":6116556,"cashHistory":[],"totalAssets":9182421,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}